111 related articles for article (PubMed ID: 29943931)
1. The effect of aprepitant and dexamethasone combination on paclitaxel-induced hypersensitivity reaction.
Yamamoto T; Natio M; Hara S; Kudo T; Miwa Y
Eur J Gynaecol Oncol; 2016; 37(6):833-836. PubMed ID: 29943931
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin.
Yahata H; Kobayashi H; Sonoda K; Shimokawa M; Ohgami T; Saito T; Ogawa S; Sakai K; Ichinoe A; Ueoka Y; Hasuo Y; Nishida M; Masuda S; Kato K
Int J Clin Oncol; 2016 Jun; 21(3):491-7. PubMed ID: 26662632
[TBL] [Abstract][Full Text] [Related]
3. Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: A double-blind randomized controlled trial.
Yanaranop M; Chaithongwongwatthana S
Asia Pac J Clin Oncol; 2016 Sep; 12(3):289-99. PubMed ID: 27098551
[TBL] [Abstract][Full Text] [Related]
4. Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.
Parinyanitikul N; Tanpipattanakul W; Poovorawan N; Rattananupong T; Laoitthi P; Sithidetphaiboon P; Thanasanvimon S; Sriuranpong V
Support Care Cancer; 2018 Jul; 26(7):2471-2477. PubMed ID: 29435713
[TBL] [Abstract][Full Text] [Related]
5. Single-dose dexamethasone paclitaxel premedication.
Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
[TBL] [Abstract][Full Text] [Related]
6. Prophylaxis for paclitaxel hypersensitivity reactions.
Kintzel PE
Ann Pharmacother; 2001 Sep; 35(9):1114-7. PubMed ID: 11573863
[TBL] [Abstract][Full Text] [Related]
7. Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy.
Xiao D; Yang Z; Shi Y; Yang W; Zhang Y
Expert Rev Clin Pharmacol; 2024; 17(5-6):525-532. PubMed ID: 38652518
[TBL] [Abstract][Full Text] [Related]
8. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
Kobierski J; Majdak E; Mielcarek P; Emerich J
Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
[TBL] [Abstract][Full Text] [Related]
9. Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies.
O'Cathail SM; Shaboodien R; Mahmoud S; Carty K; O'Sullivan P; Blagden S; Gabra H; Whear S; Kwon JS; Agarwal R
Int J Gynecol Cancer; 2013 Sep; 23(7):1318-25. PubMed ID: 23907557
[TBL] [Abstract][Full Text] [Related]
10. Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration.
Braverman AS; Rao S; Salvatti ME; Adamson B; McManus M; Pierre S
Chemotherapy; 2005 May; 51(2-3):116-9. PubMed ID: 15886470
[TBL] [Abstract][Full Text] [Related]
11. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.
Ito F; Furukawa N
Support Care Cancer; 2017 Jun; 25(6):1941-1945. PubMed ID: 28160077
[TBL] [Abstract][Full Text] [Related]
13. The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
de Castro Baccarin AL; Irene MN; de Iracema Gomes Cubero D; Luz AS; Castro SN; Sordi R; Móz LES; Del Giglio A
Support Care Cancer; 2019 Mar; 27(3):927-931. PubMed ID: 30069696
[TBL] [Abstract][Full Text] [Related]
14. Premedication strategy for weekly paclitaxel.
Quock J; Dea G; Tanaka M; Gandara D; Lara P; Lau D
Cancer Invest; 2002; 20(5-6):666-72. PubMed ID: 12197222
[TBL] [Abstract][Full Text] [Related]
15. Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy?
Aoyama T; Takano M; Miyamoto M; Yoshikawa T; Soyama H; Kato K; Ishibashi H; Iwahashi H; Nakatsuka M; Yajima I; Shimizu Y; Aizawa Y; Suguchi Y; Moriiwa M; Goto T; Sasa H; Nagaoka I; Tsuda H; Furuya K
Cancer Chemother Pharmacol; 2017 Jul; 80(1):65-69. PubMed ID: 28493032
[TBL] [Abstract][Full Text] [Related]
16. Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions.
Lansinger OM; Biedermann S; He Z; Colevas AD
J Clin Oncol; 2021 Nov; 39(32):3583-3590. PubMed ID: 34357780
[TBL] [Abstract][Full Text] [Related]
17. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
Kloover JS; den Bakker MA; Gelderblom H; van Meerbeeck JP
Br J Cancer; 2004 Jan; 90(2):304-5. PubMed ID: 14974481
[TBL] [Abstract][Full Text] [Related]
18. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
J Cancer Res Clin Oncol; 1999 Jul; 125(7):427-9. PubMed ID: 10394964
[TBL] [Abstract][Full Text] [Related]
19. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Ann Oncol; 1997 Jun; 8(6):611-4. PubMed ID: 9261533
[TBL] [Abstract][Full Text] [Related]
20. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
